FDA accepts BLA for Shire's enzyme replacement for ALL

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA accepted for review its BLA for calaspargase pegol (Cal-PEG; SHP663) as part of a multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia in a first-line setting. Its PDUFA date is Dec. 22...